M3 Valuation

Is 2413 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2413 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 2413 (¥1431.5) is trading below our estimate of fair value (¥2540.85)

Significantly Below Fair Value: 2413 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2413?

Other financial metrics that can be useful for relative valuation.

2413 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.4x
Enterprise Value/EBITDA11.4x
PEG Ratio2.1x

Price to Earnings Ratio vs Peers

How does 2413's PE Ratio compare to its peers?

The above table shows the PE ratio for 2413 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average37.9x
4483 JMDC
80.7x25.5%JP¥265.9b
4480 Medley
41.4x30.5%JP¥111.3b
3733 Software Service
11x5.9%JP¥66.2b
4820 EM Systems
18.5x9.3%JP¥39.8b
22x10.4%JP¥972.0b

Price-To-Earnings vs Peers: 2413 is good value based on its Price-To-Earnings Ratio (22x) compared to the peer average (37.9x).


Price to Earnings Ratio vs Industry

How does 2413's PE Ratio compare vs other companies in the Asian Healthcare Services Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a15.6%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a15.6%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 2413 is good value based on its Price-To-Earnings Ratio (22x) compared to the Asian Healthcare Services industry average (22.5x).


Price to Earnings Ratio vs Fair Ratio

What is 2413's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2413 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio22x
Fair PE Ratio27.5x

Price-To-Earnings vs Fair Ratio: 2413 is good value based on its Price-To-Earnings Ratio (22x) compared to the estimated Fair Price-To-Earnings Ratio (27.5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 2413 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentJP¥1,431.50
JP¥1,968.42
+37.5%
34.7%JP¥3,500.00JP¥1,280.00n/a12
Aug ’25JP¥1,366.50
JP¥2,093.42
+53.2%
28.5%JP¥3,500.00JP¥1,290.00n/a12
Jul ’25JP¥1,491.50
JP¥2,214.69
+48.5%
25.4%JP¥3,500.00JP¥1,410.00n/a13
Jun ’25JP¥1,524.00
JP¥2,271.67
+49.1%
26.0%JP¥3,500.00JP¥1,410.00n/a12
May ’25JP¥1,655.00
JP¥2,475.83
+49.6%
22.1%JP¥3,500.00JP¥1,680.00n/a12
Apr ’25JP¥2,174.50
JP¥2,581.67
+18.7%
20.2%JP¥3,600.00JP¥2,000.00n/a12
Mar ’25JP¥2,169.50
JP¥2,725.45
+25.6%
23.3%JP¥4,000.00JP¥2,000.00n/a11
Feb ’25JP¥2,057.00
JP¥2,839.09
+38.0%
19.4%JP¥4,000.00JP¥2,200.00n/a11
Jan ’25JP¥2,333.00
JP¥3,000.00
+28.6%
24.7%JP¥4,900.00JP¥2,260.00n/a11
Dec ’24JP¥2,357.00
JP¥3,000.00
+27.3%
24.7%JP¥4,900.00JP¥2,260.00n/a11
Nov ’24JP¥2,354.50
JP¥3,421.54
+45.3%
22.5%JP¥4,900.00JP¥2,260.00n/a13
Oct ’24JP¥2,716.00
JP¥3,786.15
+39.4%
22.3%JP¥6,200.00JP¥2,800.00n/a13
Sep ’24JP¥2,918.50
JP¥3,872.86
+32.7%
21.1%JP¥6,200.00JP¥2,800.00n/a14
Aug ’24JP¥3,211.00
JP¥3,930.00
+22.4%
20.5%JP¥6,200.00JP¥3,050.00JP¥1,366.5014
Jul ’24JP¥3,109.00
JP¥3,962.14
+27.4%
20.1%JP¥6,000.00JP¥3,000.00JP¥1,491.5014
Jun ’24JP¥3,114.00
JP¥3,986.43
+28.0%
19.6%JP¥6,000.00JP¥3,000.00JP¥1,524.0014
May ’24JP¥3,074.00
JP¥4,229.29
+37.6%
19.3%JP¥6,000.00JP¥3,000.00JP¥1,655.0014
Apr ’24JP¥3,301.00
JP¥4,443.57
+34.6%
22.4%JP¥7,300.00JP¥3,100.00JP¥2,174.5014
Mar ’24JP¥3,230.00
JP¥4,700.00
+45.5%
23.1%JP¥7,300.00JP¥3,600.00JP¥2,169.5013
Feb ’24JP¥3,515.00
JP¥4,919.23
+39.9%
20.8%JP¥7,200.00JP¥3,700.00JP¥2,057.0013
Jan ’24JP¥3,578.00
JP¥4,992.31
+39.5%
19.7%JP¥7,200.00JP¥3,700.00JP¥2,333.0013
Dec ’23JP¥4,192.00
JP¥5,093.85
+21.5%
20.2%JP¥7,200.00JP¥3,700.00JP¥2,357.0013
Nov ’23JP¥4,475.00
JP¥5,086.15
+13.7%
19.4%JP¥7,000.00JP¥3,700.00JP¥2,354.5013
Oct ’23JP¥4,051.00
JP¥5,043.85
+24.5%
20.3%JP¥7,000.00JP¥3,700.00JP¥2,716.0013
Sep ’23JP¥4,380.00
JP¥5,143.85
+17.4%
24.3%JP¥8,300.00JP¥3,700.00JP¥2,918.5013
Aug ’23JP¥4,669.00
JP¥5,020.77
+7.5%
25.9%JP¥8,300.00JP¥3,450.00JP¥3,211.0013

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies